<DOC>
	<DOCNO>NCT01011296</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics pharmacodynamics PF-04427429 administer intravenously healthy adult volunteer .</brief_summary>
	<brief_title>First In Human Study To Evaluate The Safety , Tolerability , Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Adult Volunteers</brief_title>
	<detailed_description>Phase 1 clinical trial</detailed_description>
	<criteria>Healthy male subject age 18 50 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight 50 kg 100 kg inclusive . Evidence personally sign date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect trial . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Willing able comply requirement use recommend highly effective contraceptive method throughout study . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , genitourinary , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , symptomatic , seasonal allergy time dose ) . Any condition possibly affect drug absorption ( eg , gastrectomy ) . History febrile illness within 5 day prior first dose . A positive urine drug screen</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>